Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data

Neha Gupta

Wed, February 18, 2026 at 10:41 AM GMT+9 2 min read

In this article:

IOVA

+1.75%

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best high-return penny stocks to buy right now. On February 5, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced data affirming a best-in-class profile for commercial Amtagvi.

Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data

The company is developing Amtagvi as a novel T cell therapy for advanced melanoma patients receiving anti-PD-1 and targeted therapies. Trial results presented at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) showed a higher response rate with Amtagvi treatment following 2 or fewer lines of therapy than the objective response rate.

Lilit Karapetyan, MD, MS of H. Lee Moffitt Cancer Center & Research Institute stated, “The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment.” An overall response rate of 44% was observed in the full cohort, with a 52% response rate among patients treated in earlier lines of therapy.

According to Daniel Kirby, Chief Commercial Officer of Iovance, the impressive response rates, paired with five-year durability and survival data, affirm a best-in-class profile and better outcomes with Amtagvi in patients. The impressive results position the company to capitalize on an unmet medical need, whereby more than 8,000 people die annually as a result of advanced melanoma.

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a biotechnology company focused on developing and commercializing tumor-infiltrating lymphocyte (TIL) therapies to treat solid tumor cancers. By leveraging a patient’s own immune system, Iovance creates personalized cancer treatments—including FDA-approved Amtagvi for melanoma—that recognize and attack cancer cells.

While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.

Terms and Privacy Policy

Privacy Dashboard

More Info